ScoreComparison
Why is Ligand Pharmaceuticals, Inc. ?
1
Company has a low Debt to Equity ratio (avg) at times
2
With a growth in Net Sales of 5.06%, the company declared Very Positive results in Jun 25
- The company has declared positive results in Jan 70 after 4 consecutive negative quarters
- NET SALES(HY) At USD 92.96 MM has Grown at 28.2%
- RAW MATERIAL COST(Y) Fallen by -4.77% (YoY)
- DEBTORS TURNOVER RATIO(HY) Highest at 4.71 times
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 68.73% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Ligand Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ligand Pharmaceuticals, Inc. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Ligand Pharmaceuticals, Inc.
57.18%
4.19
37.17%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.22%
EBIT Growth (5y)
-206.79%
EBIT to Interest (avg)
-2.40
Debt to EBITDA (avg)
0.21
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.22
Tax Ratio
69.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
1.63%
ROE (avg)
3.89%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.57
EV to EBIT
-110.49
EV to EBITDA
88.07
EV to Capital Employed
3.13
EV to Sales
10.12
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2.83%
ROE (Latest)
-9.97%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
NET SALES(HY)
At USD 92.96 MM has Grown at 28.2%
RAW MATERIAL COST(Y)
Fallen by -4.77% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 4.71 times
PRE-TAX PROFIT(Q)
Highest at USD 12.5 MM
NET PROFIT(Q)
Highest at USD 5.4 MM
EPS(Q)
Highest at USD 0.24
-17What is not working for the Company
NET PROFIT(HY)
At USD -34.5 MM has Grown at -157%
ROCE(HY)
Lowest at -9.46%
INTEREST(Q)
At USD 1.15 MM has Grown at 32.99%
Here's what is working for Ligand Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 12.5 MM has Grown at 146.37%
over average net sales of the previous four periods of USD -26.96 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 5.4 MM has Grown at 127.22%
over average net sales of the previous four periods of USD -19.83 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 92.96 MM has Grown at 28.2%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
Highest at USD 12.5 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 5.4 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.24
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 4.71 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -4.77% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ligand Pharmaceuticals, Inc.
Interest
At USD 1.15 MM has Grown at 32.99%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
